{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:00:28Z","timestamp":1787162428398,"version":"build-2736575974"},"reference-count":50,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China Excellent Young Scientists","award":["82222062"],"award-info":[{"award-number":["82222062"]}]},{"name":"National Natural Science Foundation of China Excellent Young Scientists","award":["BK20220064"],"award-info":[{"award-number":["BK20220064"]}]},{"name":"Jiangsu Provincial Outstanding Youth Foundation Project","award":["82222062"],"award-info":[{"award-number":["82222062"]}]},{"name":"Jiangsu Provincial Outstanding Youth Foundation Project","award":["BK20220064"],"award-info":[{"award-number":["BK20220064"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is one of the leading infectious causes of adult mortality worldwide. The Bacillus Calmette\u2013Gu\u00e9rin (BCG) vaccine is currently the only approved vaccine for TB prevention, but its protective efficacy against adult pulmonary TB is limited, and it lacks effective protection against primary or latent TB infection. There is an urgent need to develop more effective preventive TB vaccines. Currently, preventive TB vaccines under clinical investigation globally include live attenuated vaccines, recombinant subunit vaccines, viral vector vaccines, and mRNA vaccines. This article reviews and summarizes recent progress in the clinical development of preventive TB vaccines, analyzing and comparing their safety, immunogenicity, and protective efficacy. It also explores novel strategies for next-generation TB vaccine development, aiming to provide insights and directions for future research.<\/jats:p>","DOI":"10.3390\/vaccines13090959","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T12:04:55Z","timestamp":1757505895000},"page":"959","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Recent Advances in Clinical Research of Prophylactic Vaccines Against Tuberculosis"],"prefix":"10.3390","volume":"13","author":[{"given":"Buyun","family":"Xu","sequence":"first","affiliation":[{"name":"National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing 210000, China"},{"name":"Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjuan","family":"Yuan","sequence":"additional","affiliation":[{"name":"National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing 210000, China"},{"name":"Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Yang","sequence":"additional","affiliation":[{"name":"National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing 210000, China"},{"name":"Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Huang","sequence":"additional","affiliation":[{"name":"National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing 210000, China"},{"name":"School of Public Health, Southeast University, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7033-5151","authenticated-orcid":false,"given":"Jingxin","family":"Li","sequence":"additional","affiliation":[{"name":"National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing 210000, China"},{"name":"Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongming","family":"Tan","sequence":"additional","affiliation":[{"name":"National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing 210000, China"},{"name":"Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/S0140-6736(19)30308-3","article-title":"Tuberculosis","volume":"393","author":"Furin","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/S0140-6736(15)00151-8","article-title":"Tuberculosis","volume":"387","author":"Dheda","year":"2016","journal-title":"Lancet"},{"key":"ref_3","unstructured":"(2024, December 10). Global Tuberculosis Report 2024. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240101531."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3934\/microbiol.2021007","article-title":"Bacillus calmette-guerin (BCG): The adroit vaccine","volume":"7","author":"Adesanya","year":"2021","journal-title":"AIMS Microbiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1128\/IAI.01999-06","article-title":"Lack of immune responses to mycobacterium tuberculosis DosR regulon proteins following mycobacterium bovis BCG vaccination","volume":"75","author":"Lin","year":"2007","journal-title":"Infect Immun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3390\/vaccines1020120","article-title":"Nonclinical development of BCG replacement vaccine candidates","volume":"1","author":"Velmurugan","year":"2013","journal-title":"Vaccines"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e00439-16","DOI":"10.1128\/CVI.00439-16","article-title":"Safety and immunogenicity of the recombinant mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in south africa","volume":"24","author":"Loxton","year":"2017","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/S1473-3099(22)00222-5","article-title":"Safety and immunogenicity of VPM1002 versus BCG in south african newborn babies: A randomised, phase 2 non-inferiority double-blind controlled trial","volume":"22","author":"Cotton","year":"2022","journal-title":"Lancet Infect Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14760584.2017.1324303","article-title":"MTBVAC from discovery to clinical trials in tuberculosis-endemic countries","volume":"16","author":"Marinova","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.1016\/j.vaccine.2021.06.049","article-title":"MTBVAC, a live TB vaccine poised to initiate efficacy trials 100 years after BCG","volume":"39","author":"Martin","year":"2021","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1016\/j.vaccine.2013.07.051","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated m. Tuberculosis-based vaccine to enter clinical trials","volume":"31","author":"Arbues","year":"2013","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"11491","DOI":"10.1073\/pnas.1406693111","article-title":"Evolutionary history of tuberculosis shaped by conserved mutations in the PhoPR virulence regulator","volume":"111","author":"Malaga","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S2213-2600(15)00435-X","article-title":"Safety of human immunisation with a live-attenuated mycobacterium tuberculosis vaccine: A randomised, double-blind, controlled phase i trial","volume":"3","author":"Spertini","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S2213-2600(19)30251-6","article-title":"Live-attenuated mycobacterium tuberculosis vaccine MTBVAC versus BCG in adults and neonates: A randomised controlled, double-blind dose-escalation trial","volume":"7","author":"Tameris","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.arbres.2023.09.009","article-title":"MTBVAC: A tuberculosis vaccine candidate advancing towards clinical efficacy trials in TB prevention","volume":"59","author":"Lacamara","year":"2023","journal-title":"Arch Bronconeumol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1097\/QAD.0000000000000343","article-title":"Safety and immunogenicity of the m72\/as01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: A phase i\/II, randomized trial","volume":"28","author":"Thacher","year":"2014","journal-title":"Aids"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2459","DOI":"10.1097\/MD.0000000000002459","article-title":"A randomized, controlled safety, and immunogenicity trial of the m72\/as01 candidate tuberculosis vaccine in HIV-positive indian adults","volume":"95","author":"Kumarasamy","year":"2016","journal-title":"Medicine"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.vaccine.2015.05.088","article-title":"Safety and immunogenicity of candidate vaccine m72\/as01e in adolescents in a TB endemic setting","volume":"33","author":"Geldenhuys","year":"2015","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tube.2016.07.005","article-title":"Safety and immunogenicity of the m72\/as01e candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study","volume":"100","author":"Gillard","year":"2016","journal-title":"Tuberculosis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of m72\/as01(e) vaccine to prevent tuberculosis","volume":"379","author":"Hatherill","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of m72\/as01(e) vaccine to prevent tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_22","unstructured":"(2024, December 13). Late-Stage Trial for Tuberculosis Vaccine Candidate Underway in South Africa|News|Wellcome. Available online: https:\/\/wellcome.org\/news\/late-stage-trial-tuberculosis-vaccine-candidate-underway-south-africa."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tkachuk, A.P., Gushchin, V.A., Potapov, V.D., Demidenko, A.V., Lunin, V.G., and Gintsburg, A.L. (2017). Multi-subunit BCG booster vaccine GamTBvac: Assessment of immunogenicity and protective efficacy in murine and guinea pig TB models. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0176784"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Vasina, D.V., Kleymenov, D.A., Manuylov, V.A., Mazunina, E.P., Koptev, E.Y., Tukhovskaya, E.A., Murashev, A.N., Gintsburg, A.L., Gushchin, V.A., and Tkachuk, A.P. (2019). First-in-human trials of GamTBvac, a recombinant subunit tuberculosis vaccine candidate: Safety and immunogenicity assessment. Vaccines, 7.","DOI":"10.3390\/vaccines7040166"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Tkachuk, A.P., Bykonia, E.N., Popova, L.I., Kleymenov, D.A., Semashko, M.A., Chulanov, V.P., Fitilev, S.B., Maksimov, S.L., Smolyarchuk, E.A., and Manuylov, V.A. (2020). Safety and immunogenicity of the GamTBvac, the recombinant subunit tuberculosis vaccine candidate: A phase II, multi-center, double-blind, randomized, placebo-controlled study. Vaccines, 8.","DOI":"10.3390\/vaccines8040652"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Orr, M.T., Beebe, E.A., Hudson, T.E., Moon, J.J., Fox, C.B., Reed, S.G., and Coler, R.N. (2014). A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0083884"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s40121-023-00806-0","article-title":"Safety and immunogenicity of the ID93 + GLA-SE tuberculosis vaccine in BCG-vaccinated healthy adults: A randomized, double-blind, placebo-controlled phase 2 trial","volume":"12","author":"Choi","year":"2023","journal-title":"Infect Dis Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41541-023-00666-2","article-title":"A protective, single-visit TB vaccination regimen by co-administration of a subunit vaccine with BCG","volume":"8","author":"Dijkman","year":"2023","journal-title":"NPJ Vaccines"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Guo, X., Lu, J., Li, J., Du, W., Shen, X., Su, C., Wu, Y., Zhao, A., and Xu, M. (2022). The subunit AEC\/BC02 vaccine combined with antibiotics provides protection in mycobacterium tuberculosis-infected guinea pigs. Vaccines, 10.","DOI":"10.3390\/vaccines10122164"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1128","article-title":"Recombinant modified vaccinia virus ankara expressing antigen 85a boosts BCG-primed and naturally acquired antimycobacterial immunity in humans","volume":"10","author":"McShane","year":"2004","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1086\/590185","article-title":"Safety and immunogenicity of a new tuberculosis vaccine, MVA85a, in healthy adults in south africa","volume":"198","author":"Hawkridge","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.vaccine.2019.10.102","article-title":"A phase i trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85a prime\u2014MVA85a boost in healthy UK adults","volume":"38","author":"Wilkie","year":"2020","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/infdis\/jiw467","article-title":"Induction of an immune-protective t-cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in humans","volume":"214","author":"Jeyanathan","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e155655","DOI":"10.1172\/jci.insight.155655","article-title":"Aerosol delivery, but not intramuscular injection, of adenovirus-vectored tuberculosis vaccine induces respiratory-mucosal immunity in humans","volume":"7","author":"Jeyanathan","year":"2022","journal-title":"JCI Insight"},{"key":"ref_35","first-page":"558","article-title":"Evaluation of the immunotoxicity and allergenicity of a new intranasal influenza vector vaccine against tuberculosis carrying TB10.4 and HspX antigens","volume":"26","author":"Stosman","year":"2023","journal-title":"Iran. J. Basic Med. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"100163","DOI":"10.1016\/j.cellin.2024.100163","article-title":"Optimizing antigen selection for the development of tuberculosis vaccines","volume":"3","author":"Yang","year":"2024","journal-title":"Cell Insight"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.chom.2017.05.012","article-title":"Antigen availability shapes t cell differentiation and function during tuberculosis","volume":"21","author":"Moguche","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gong, W., and Wu, X. (2021). Differential diagnosis of latent tuberculosis infection and active tuberculosis: A key to a successful tuberculosis control strategy. Front Microbiol., 12.","DOI":"10.3389\/fmicb.2021.745592"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/acs.bioconjchem.3c00273","article-title":"Design and characterization of a multistage peptide-based vaccine platform to target mycobacterium tuberculosis infection","volume":"34","author":"Bellini","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e190230","DOI":"10.1172\/JCI190230","article-title":"Sensing mycobacteria through unconventional pathways","volume":"135","author":"Almeida","year":"2025","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Romano, M., Squeglia, F., Kramarska, E., Barra, G., Choi, H., Kim, H., Ruggiero, A., and Berisio, R. (2023). A structural view at vaccine development against m. Tuberculosis. Cells, 12.","DOI":"10.3390\/cells12020317"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2019027047","article-title":"Nanoparticulate carriers used as vaccine adjuvant delivery systems","volume":"36","author":"Wang","year":"2019","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.vaccine.2019.04.055","article-title":"Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity","volume":"37","author":"Shi","year":"2019","journal-title":"Vaccine"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S1473-3099(19)30625-5","article-title":"The status of tuberculosis vaccine development","volume":"20","author":"Schrager","year":"2020","journal-title":"Lancet Infect Dis."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kim, H., Choi, H., and Shin, S.J. (2023). Bridging the gaps to overcome major hurdles in the development of next-generation tuberculosis vaccines. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1193058"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Dijkman, K., Coler, R.N., and Joosten, S.A. (2022). Editorial: Beyond th1: Novel concepts in tuberculosis vaccine immunology. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1059011"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Rodo, M.J., Rozot, V., Nemes, E., Dintwe, O., Hatherill, M., Little, F., and Scriba, T.J. (2019). A comparison of antigen-specific t cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007643"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2016.08.072","article-title":"A functional role for antibodies in tuberculosis","volume":"167","author":"Lu","year":"2016","journal-title":"Cell"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hunter, L., Hingley-Wilson, S., Stewart, G.R., Sharpe, S.A., and Salguero, F.J. (2021). Dynamics of macrophage, t and b cell infiltration within pulmonary granulomas induced by mycobacterium tuberculosis in two non-human primate models of aerosol infection. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.776913"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Herrera-Van Oostdam, A.S., Castaneda-Delgado, J.E., Oropeza-Valdez, J.J., Borrego, J.C., Monarrez-Espino, J., Zheng, J., Mandal, R., Zhang, L., Soto-Guzman, E., and Fernandez-Ruiz, J.C. (2021). Immunometabolic signatures predict risk of progression to sepsis in COVID-19. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0256784"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/959\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:17Z","timestamp":1760035397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/13\/9\/959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":50,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["vaccines13090959"],"URL":"https:\/\/doi.org\/10.3390\/vaccines13090959","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}